Final formulation

Mesalazine, the active pharmaceutical ingredient (API), is used in medicine to treat inflammatory bowel disease. Ferring’s product PENTASA^® contains Mesalazine API manufactured by Syntese.

PENTASA^® (mesalazine) is Ferring’s product used for the treatment and long-term management of inflammatory bowel diseases (IBD) (Ulcerative colitis and Crohn’s disease).

PENTASA is prescribed to treat the mild to moderate symptoms of active IBD as well as being used widely as maintenance therapy to reduce the risk of recurrent attacks.

PENTASA is available orally as tablets and granules (sachets) within Europe and the rest of the world, excluding the USA. In the USA, Shire US, Inc. sells PENTASA under a trademark license from Ferring.Topical formulations (suppositories and enemas) are also available for administration via the rectum, allowing a high concentration of the drug to be in contact with areas of inflammation at the lower end of the digestive tract.

Oral PENTASA has a prolonged-release formulation, helping to ensure release of active mesalazine throughout the entire length of the intestine from the duodenum to the rectum. Topical PENTASA formulations (enemas and suppositories) enable active mesalazine to remain in contact with the inflamed mucosa for several hours.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.